<DOC>
	<DOCNO>NCT02206841</DOCNO>
	<brief_summary>This study design establishment non-alcoholic fatty liver disease patient cohort development marker predict histologic progression liver fibrosis .</brief_summary>
	<brief_title>Establishment NAFLD Cohort Development Fibrosis Markers</brief_title>
	<detailed_description>- Acoustic radiation force impulse elastography - Liver tissue ( frozen tissue , paraffin block ) - Whole blood , Serum - Fat amount ratio CT ( Visceral adipose tissue , Subcutaneous adipose tissue amount ) - Body composition analyzer ( InBody scale ) : Total fat/muscle mass appendicular skeletal muscle mass</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Patients histologically confirm fatty liver disease Patients radiologically confirm fatty liver disease History significant alcohol consumption Viral hepatitis Autoimmune hepatitis Metabolic diseases ( e.g . hemochromatosis , M. Wilson , alpha 1antitrypsin deficiency ) Hepatotoxic medication ( e.g . amiodarone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>fibrosis</keyword>
	<keyword>marker</keyword>
</DOC>